<DOC>
	<DOCNO>NCT00564941</DOCNO>
	<brief_summary>This study evaluate safety efficacy deferasirox transfusion dependent Myelodysplastic Syndrome , Beta-thalassaemia major patient chronic iron overload</brief_summary>
	<brief_title>Evaluating Efficacy Deferasirox Transfusion Dependent Chronic Anaemias ( Myelodysplastic Syndrome , Beta-thalassaemia Patients ) With Chronic Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion criterion : In outpatient myelodysplasia / risk low intermedier1 accord International Prognostic Scoring System ( IPSS ) confirm bone marrow evaluation within 3 month/ beta thalassaemia major patient , chronic iron overload , consequence frequent blood transfusion Serum ferritin &gt; 1800 Âµg/L Age : 1880 year men woman Chronic iron overload cause least 30 unit maximum 100 unit blood pack red blood cell Deferoxamin therapy contraindicate inadequate unable use recommend dose due intolerability reason Eastern Cooperative Oncology Group ( ECOG ) performance status score 02 write informed consent Exclusion criterion : beta thalassaemia minor , haemosiderosis cause chronic transfusional iron overload , patient impair renal function ( Creatinin clearance &lt; 60 ml/ min ) , pregnancy , lactation , patient childbearing potential unwilling use contraceptive precaution know hypersensitivity deferasirox ingredient , impaired hepatic function ( SGOT , SGPT 5x UNL ) . Patients severely ill due underlie disease progression severe concomitant disease . Patients poor prognosis karyotype patient malabsorption cause inflammatory bowel disease , gastrectomy , pancreatitis medical condition History nephrotic syndrome Significant proteinuria Patients previous history clinically relevant ocular toxicity relate iron chelation Patients positive test HIV Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>beta-Thalassemia</keyword>
	<keyword>Iron Overload</keyword>
	<keyword>Iron Chelating Agents</keyword>
	<keyword>deferasirox</keyword>
</DOC>